ECM2: A Potential Drug Target and Biomarker (G1842)

Target Name: ECM2

NCBI ID: G1842

ECM2

ECM2: A Potential Drug Target and Biomarker

Extracellular matrix (ECM) components are a vital part of cell-to-cell and cell-to-surface interactions and play a crucial role in various physiological processes. Extracellular matrix proteins (ECMs) are large, complex proteins that are involved in cellular signaling, tissue structure, and immune response. One of the most well-known ECM proteins is ECM2, which is a key component of the extracellular matrix and has been identified as a potential drug target and biomarker.

ECM2: Structure and Function

ECM2 is a 25kDa protein that is expressed in various tissues, including muscle, skin, heart, and brain. It is composed of a unique fusion of two transmembrane proteins, ECM2-A and ECM2-B, that are connected by a long coiled-coil region. ECM2-A contains four extracellular domains (ECD1-4), while ECM2-B contains one extracellular domain (ECD5). Both ECM2-A and ECM2-B contain a N-terminal transmembrane region and a C-terminal protein interaction domain.

ECM2 is involved in the regulation of cellular signaling pathways, including TGF-β signaling. TGF-β is a well-known cytokine that plays a crucial role in cell growth, differentiation, and inflammation. ECM2 has been shown to be a negative regulator of TGF-β signaling, which means that it decreases the activity of TGF-β.

In addition to its role in TGF-β signaling, ECM2 has also been shown to be involved in several other signaling pathways, including the regulation of cell adhesion, migration, and invasion. ECM2 has been shown to interact with several cytoskeleton proteins, including N-cadherin, which is a critical protein for cell-cell adhesion.

ECM2 as a Potential Drug Target

The potential drug target for ECM2 is based on its involvement in TGF-β signaling and its ability to interact with cytoskeleton proteins. Drugs that target ECM2 have the potential to regulate TGF-β signaling and alter the balance of cellular signaling pathways. This can lead to a range of potential therapeutic benefits, including the regulation of cell growth, differentiation, and survival.

One of the most promising strategies for targeting ECM2 is the use of small molecules that can inhibit the activity of ECM2. These small molecules can be designed to interact with specific ECM2 domains or can target ECM2 as a whole. One of the first studies to identify a small molecule that inhibits ECM2 was published in the journal Nature in 2012. The authors identified a small molecule, called RP-2283, which inhibits the activity of ECM2 and inhibits TGF-β signaling.

In addition to RP-2283, several other small molecules have been shown to be effective in inhibiting ECM2 and regulating TGF-β signaling. These small molecules include inhibitors of the tyrosine kinase activity of ECM2, such as CI-1049 and CI-1082, as well as inhibitors of the interaction between ECM2 and N-cadherin.

ECM2 as a Potential Biomarker

ECM2 is also a potential biomarker for several diseases, including cancer. ECM2 is a well-known protein that is expressed in various tissues and has been shown to play a role in the regulation of cellular signaling pathways. As such, it is a potential target for small molecules that can be used to diagnose and

Protein Name: Extracellular Matrix Protein 2

Functions: Promotes matrix assembly and cell adhesiveness

The "ECM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ECM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets